PKM2 metabolic activator slows lung cancer xenograft growth

被引：0
|
作者：
Parnell, Mark [1 ]
Foulks, Jason M. [1 ]
Nix, Rebecca [1 ]
Luo, Bai [1 ]
Senina, Anna [1 ]
Xu, Yong [1 ]
Saunders, Michael [1 ]
Hol, Koc-Kan [1 ]
McCullar, Michael V. [1 ]
Kanner, Steven B. [1 ]
机构：
[1] Astex Pharmaceut Inc, Salt Lake City, UT USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-3226
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3226
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Role of PKM2 in directing the metabolic fate of glucose in cancer: a potential therapeutic target
    van Niekerk, Gustav
    Engelbrecht, Anna-Mart
    CELLULAR ONCOLOGY, 2018, 41 (04) : 343 - 351
  • [22] Knockdown of PKM2 Enhances Radiosensitivity of Non-small cell Lung Cancer
    Shijiang Wang
    Yan Ma
    Peiguo Wang
    Zheng Song
    Bin Liu
    Xindong Sun
    Huaqi Zhang
    Jinming Yu
    Cell Biochemistry and Biophysics, 2015, 73 : 21 - 26
  • [23] Knockdown of PKM2 Enhances Radiosensitivity of Non-small cell Lung Cancer
    Wang, Shijiang
    Ma, Yan
    Wang, Peiguo
    Song, Zheng
    Liu, Bin
    Sun, Xindong
    Zhang, Huaqi
    Yu, Jinming
    CELL BIOCHEMISTRY AND BIOPHYSICS, 2015, 73 (01) : 21 - 26
  • [24] Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice
    Shi, Hua-shan
    Li, Dan
    Zhang, Jing
    Wang, Yong-sheng
    Yang, Li
    Zhang, Hai-long
    Wang, Xian-huo
    Mu, Bo
    Wang, Wei
    Ma, Yu
    Guo, Fu-chun
    Wei, Yu-quan
    CANCER SCIENCE, 2010, 101 (06): : 1447 - 1453
  • [25] Oncogenic tyrosine kinases phosphorylate and inhibit PKM2 to provide a metabolic advantage to tumor growth
    Hitosugi, Taro
    Kang, Sumin
    Heiden, Matthew G. Vander
    Chung, Tae-Wook
    Lonial, Sagar
    Wang, Xu
    Chen, Georgia Z.
    Xie, Jianxin
    Gu, Ting-Lei
    Polakiewicz, Roberto D.
    Roesel, Johannes L.
    Boggon, Titus
    Khuri, Fadlo
    Gilliland, D. Gary
    Cantley, Lewis C.
    Kaufman, Jonathan
    Chen, Jing
    CANCER RESEARCH, 2010, 70
  • [26] Identification of a new pyruvate kinase M2 isoform (PKM2) activator for the treatment of non-small-cell lung cancer (NSCLC)
    Li, Run-Ze
    Fan, Xing-Xing
    Shi, Dan-Feng
    Zhu, Guo-Yuan
    Wang, Yu-Wei
    Luo, Lian-Xiang
    Pan, Hu-Dan
    Yao, Xiao-Jun
    Leung, Elaine Lai-Han
    Liu, Liang
    CHEMICAL BIOLOGY & DRUG DESIGN, 2018, 92 (05) : 1851 - 1858
  • [27] Urinary PKM2 in muscle invasive bladder cancer
    Matye, David
    Leak, Juliann
    Abbott, Erika
    Woolbright, Benjamin
    Taylor, John
    CANCER RESEARCH, 2024, 84 (06)
  • [28] Changes in PKM2 Associate with Prostate Cancer Progression
    Wong, Nicholas
    Yan, Judy
    Ojo, Diane
    De Melo, Jason
    Cutz, Jean-Claude
    Tang, Damu
    CANCER INVESTIGATION, 2014, 32 (07) : 330 - 338
  • [29] THE ALLOSTERIC PKM2 ACTIVATOR OF TEPP-46 PROTECTS FROM ALCOHOLIC STEATOHEPATITIS VIA THE REGULATION OF BOTH PKM2 TERAMERIZATION AND NUCLEAR TRANSACTIVATION.
    Ouyang, Xinshou
    Suyavaran, Arumugam
    Mehal, Wajahat Z.
    HEPATOLOGY, 2019, 70 : 813A - 814A
  • [30] Nuclear translocation of PKM2 mediates keratinocyte metabolic reprogramming in psoriasis
    Yang, Luting
    Zhang, Jie
    Hu, Chunqing
    Chen, Xiaowen
    Yang, Yang
    Tang, Huihao
    Ding, Xiaolei
    Yan, Yaping
    EXPERIMENTAL DERMATOLOGY, 2023, 32 (11) : 1960 - 1970
12345